Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Cancer Research

• Publication date

  2001-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11489837
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors

  2004cited by this paper
• A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.

  2000cited by this paper
• Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.

  2000cited by this paper
• Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.

  2000cited by this paper
• Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

  2000cited by this paper
• Chemosensitisation of malignant melanoma by BCL2 antisense therapy.

  2000cited by this paper
• Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A.

  1999cited by this paper
• Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.

  1999cited by this paper
• Improved Detection of Apoptotic Cells Using a Modified In Situ TUNEL Technique

  1999influential reference
• BCL-2 family members and the mitochondria in apoptosis.

  1999cited by this paper
• Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RIα subunit: p53-independent mechanism of action

  1999cited by this paper
• Molecular effects of paclitaxel: Myths and reality (a critical review)

  1999cited by this paper
• Obstacles and opportunities for the use of health‐related quality‐of‐life assessment in pediatric cancer clinical trials (discussion)

  1999cited by this paper
• BCL-2 Is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at G2/M

  1999cited by this paper
• Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy.

  1999cited by this paper
• Apoptosis and cancer drug targeting.

  1999cited by this paper
• Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis.

  1999cited by this paper
• Antisense oligonucleotide inhibition of serine/threonine kinases: an innovative approach to cancer treatment.

  1999cited by this paper
• Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.

  1999cited by this paper
• Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

  1999cited by this paper
• Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

  1999cited by this paper
• Novel function of the regulatory subunit of protein kinase A: regulation of cytochrome c oxidase activity and cytochrome c release.

  1998cited by this paper
• Mechanisms and consequences of activation of protein kinase B/Akt.

  1998cited by this paper
• bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

  1998cited by this paper
• Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

  1998cited by this paper
• Dysregulation of apoptosis in cancer.

  1998cited by this paper
• Involvement of Microtubules in the Regulation of Bcl2 Phosphorylation and Apoptosis through Cyclic AMP-Dependent Protein Kinase

  1998cited by this paper
• Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.

  1998cited by this paper
• Dysregulation of apoptosis in cancer.

  1998cited by this paper
• Antisense therapeutics.

  1998cited by this paper
• Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.

  1997cited by this paper
• The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-Receptor

  1997cited by this paper
• Regulation of Bcl‐2 Protein Expression in Human Neuroblastoma SH‐SY5Y Cells: Positive and Negative Effects of Protein Kinases C and A, Respectively

  1996cited by this paper
• Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.

  1996cited by this paper
• cAMP-dependent protein kinase: role in normal and malignant growth.

  1995cited by this paper
• A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth

  1995cited by this paper
• Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

  1995cited by this paper
• Large-Scale Synthesis, Purification, and Analysis of Oligodeoxynucleotide Phosphorothioates

  1994cited by this paper
• Down‐regulation of riα subunit of camp‐dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c‐ha‐ras and c‐erbb‐2 proto‐oncogenes

  1993cited by this paper
• Reduction of RIα Subunit of cAMP‐dependent Protein Kinase Expression Induces Growth Inhibition of Human Mammary Epithelial Cells Transformed by TGF‐α, c‐Ha‐ras, and c‐erbB‐2 Genes

  1993cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper

• Anti-proliferative effect of PRKAR1A gene suppression by RNA interference in cholangiocarcinoma cell line

  2017cites this paper
• Dichotomous role of protein kinase A type I (PKAI) in the tumor microenvironment: a potential target for 'two-in-one' cancer chemoimmunotherapeutics.

  2015cites this paper
• Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases.

  2012cites this paper
• Silencing of anti-apoptotic transmembrane protein lifeguard sensitizes solid tumor cell lines MCF-7 and SW872 to perifosine-induced cell death activation.

  2011cites this paper
• Protein Kinase A: The Enzyme and Cyclic AMP Signaling

  2011cites this paper
• Targeting the Tumor Microenvironment: Focus on Angiogenesis

  2011cites this paper
• Folate-immunoglobulin G as an anticancer therapeutic antibody.

  2010cites this paper
• RAS and PKA pathways in cancer: new insight from transcriptional analysis.

  2008cites this paper
• Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy.

  2007cites this paper
• Oblimersen in the treatment of metastatic melanoma.

  2007cites this paper
• Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies.

  2006cites this paper
• New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway.

  2006cites this paper
• Effect of combined antisense oligonucleotides against high-glucose- and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability.

  2006cites this paper
• Significance of Protein Kinase A in Cancer

  2006cites this paper
• Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2.

  2006cites this paper
• Terapia antisentido en oncología: situación actual

  2005cites this paper
• Novel agents in development for the treatment of melanoma

  2005cites this paper
• Development of molecular targeted anticancer agents: successes, failures and future directions.

  2005cites this paper
• [Antisense therapy in oncology: present situation].

  2005cites this paper
• Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer

  2005cites this paper
• The Intrinsic (Mitochondrial) Death Pathway and New Cancer Therapeutics: Bcl-2 Family in Focus

  2005cites this paper
• The Genetics of Sporadic Colon Cancer

  2004cites this paper
• Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy

  2004cites this paper
• Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack.

  2004cites this paper
• Pro‐apoptotic therapy with the oligonucleotide GenasenseTM (oblimersen sodium) targeting Bcl‐2 protein expression enhances the biological anti‐tumour activity of rituximab

  2004cites this paper
• Antisense oligonucleotide-based therapeutics for cancer

  2003cites this paper
• Antisense therapeutics: from theory to clinical practice.

  2003cites this paper
• Antisense DNAs as targeted genetic medicine to treat cancer

  2003cites this paper
• Gab1, SHP-2 and other novel regulators of Ras: targets for anticancer drug discovery?

  2003cites this paper
• Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells

  2003cites this paper
• [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results].

  2003cites this paper
• Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity

  2003cites this paper
• Antisense Targeting Protein Kinase A Type I as a Drug for Integrated Strategies of Cancer Therapy

  2003cites this paper
• The future of antisense therapy: combination with anticancer treatments

  2003cites this paper
• Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

  2003cites this paper
• Proapoptotische Therapie mit Oblimersen (bcl-2-Antisense-Oligonukleotid) – Übersicht über präklinische und klinische Daten

  2003cites this paper
• Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein

  2003cites this paper
• Oblimersen Bcl-2 Antisense: Facilitating Apoptosis in Anticancer Treatment

  2002cites this paper
• Evoluzione della Tecnologia e Degli Obiettivi Clinici della Terapia Antitumorale

  2002cites this paper
• Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy

  2002cites this paper
• Protein kinase A type I: a target for cancer therapy.

  2002cites this paper